<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795624</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042101</org_study_id>
    <nct_id>NCT02795624</nct_id>
  </id_info>
  <brief_title>Vascular Aging in Flight Attendants With Occupational Secondhand Smoke Exposure</brief_title>
  <official_title>Vascular Aging in Flight Attendants With Occupational Secondhand Smoke Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1. Characterize the long-term effects of secondhand smoke (SHS) on vascular&#xD;
      health in pre-ban flight attendants (FAs). Investigators will measure arterial stiffness&#xD;
      (pulse wave velocity and augmentation index) and endothelial dysfunction (reactive hyperemia&#xD;
      index) in the pre-ban FA cases, and compare to the cardiovascular risk-factor matched&#xD;
      Framingham controls.&#xD;
&#xD;
      It is hypothesized that pre-ban FA cases have increased arterial stiffness (higher pulse wave&#xD;
      velocity and higher augmentation index) and increased endothelial dysfunction (lower reactive&#xD;
      hyperemia index) compared to Framingham controls.&#xD;
&#xD;
      Specific Aim 2. Determine the extent in which remote pre-ban SHS exposure (hours) is&#xD;
      associated with increased arterial stiffness or endothelial dysfunction.&#xD;
&#xD;
      Investigators hypothesize that pre-ban SHS exposure is positively associated with both&#xD;
      increased arterial stiffness and increased endothelial dysfunction.&#xD;
&#xD;
      Specific Aim 3. Investigators will calculate the cardiovascular risk scores (Framingham,&#xD;
      Reynolds, and ASCVD) by using subjects' age, blood pressure, family history, lipid panel, and&#xD;
      highly sensitive C-reactive protein. Investigators will explore the association of the risk&#xD;
      scores with measures of vascular aging (arterial stiffness and endothelial dysfunction).&#xD;
      These scores do not include SHS exposure. Investigators will also test the additive value of&#xD;
      SHS exposure in increasing arterial stiffness and endothelial dysfunction using the risk&#xD;
      scores as an adjustment value.&#xD;
&#xD;
      It is hypothesized that the cardiovascular risk scores are associated with vascular aging&#xD;
      (arterial stiffness and endothelial dysfunction), and that the association between SHS&#xD;
      exposure and vascular aging remains significant after adjusting for the cardiovascular risk&#xD;
      scores.&#xD;
&#xD;
      The significance of this proposal and impact will be (1) mechanistic insights into how remote&#xD;
      SHS exposure leads to hypertension and vascular stiffness, (2) increased understanding of how&#xD;
      SHS exposure can increase risk of cardiovascular disease, which is the number one cause of&#xD;
      death in the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a cohort study, in which investigators will assess for evidence of&#xD;
      accelerated vascular aging in 300 pre-ban FAs with pre-ban SHS exposure, and compare their&#xD;
      vascular measures of arterial stiffness and endothelial dysfunction to those of age and&#xD;
      risk-factor matched Framingham controls. It is hypothesized that pre-ban FAs have increased&#xD;
      arterial stiffness and endothelial dysfunction compared to the Framingham subjects, related&#xD;
      to SHS exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Dysfunction (RHI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Reactive hyperemia index (RHI) will be measured by Peripheral Arterial Tonometry, which reflects endothelial dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Stiffness (PWV)</measure>
    <time_frame>Baseline</time_frame>
    <description>During Pulse Wave analysis, pulse wave velocity (PWV) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Stiffness (AIx)</measure>
    <time_frame>Baseline</time_frame>
    <description>During Pulse Wave analysis, augmentation index (AIx) wil be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>Framingham 10-year risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>Reynolds 10-year risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>American Heart Association/ACC 10-year risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>American Heart Association/ACC Lifetime risk</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Vascular Aging</condition>
  <condition>Secondhand Smoking</condition>
  <arm_group>
    <arm_group_label>Flight attendants</arm_group_label>
    <description>Flight attendants</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.</description>
    <arm_group_label>Flight attendants</arm_group_label>
    <other_name>Breathing test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulse Wave Analysis</intervention_name>
    <description>It is a non-invasive assessment of the pulse character</description>
    <arm_group_label>Flight attendants</arm_group_label>
    <other_name>PWA</other_name>
    <other_name>Arterial stiffness test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral arterial tonometry</intervention_name>
    <description>It is a non-invasive method to measure endothelial dysfunction.</description>
    <arm_group_label>Flight attendants</arm_group_label>
    <other_name>Endothelial function test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Flight attendants that are 40 years of age and older, with prior occupation secondhand&#xD;
        smoke (SHS) exposure pre- and post- smoking ban.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 years of age and older;&#xD;
&#xD;
          -  Flight attendant, including current or past employment with the airlines;&#xD;
&#xD;
          -  Non-smoking flight attendant (current and prior, defined as smoking &lt;100 cigarettes in&#xD;
             your lifetime);&#xD;
&#xD;
          -  Exposed to secondhand tobacco smoke for at least one year, while working on the&#xD;
             aircrafts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Raynaud's syndrome&#xD;
&#xD;
          -  Had mastectomy or arm/hand abnormality in which blood pressure cannot be measured on&#xD;
             the arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.Noel Bairey Merz, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Women's Heart Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Noel Bairey Merz</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

